Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma

Figure 1 Study design. A total of 129 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 (n = 40) and stage A hepatocellular carcinoma (HCC) (n = 89) who underwent transarterial chemoembolization (TACE) were retrospectively enrolled. Op: Operation.

Figure 2 Cumulative survival graph of patients.

Figure 3 Cumulative patient survival classified by each risk factor. CPS: Child-Pugh score; AV: Arterio-venous.

Figure 4 Cumulative patient survival classified by the number of risk factors. Risk factors were Child-Pugh score > 5, presence of arterio-venous shunt, amount of lipiodol used > 7 mL during transarterial chemoembolization (TACE), and female gender.

Figure 5 One, 5, and 10-year survival rates classified by Child-Pugh score. Risk factors were Child-Pugh score > 5, presence of arterio-venous shunt, amount of lipiodol used > 7 mL during transarterial chemoembolization (TACE), and female gender.